Mather Group’s Xenon Pharmaceuticals XENE Stock Holding History

Mather Group’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.26K	Buy	+34	New	+$2.02K	﹤0.01%	2126

Other funds holding XENE

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Elmwood Wealth Management Berkeley, California $416M AUM 11.87% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return

Mather Group's XENE Position: Q3 2026 in Review

Mather Group opened a new position in Xenon Pharmaceuticals (XENE) in Q3 2026: 34 shares worth $1.26K. The stake represents ﹤0.01% of the portfolio and ranks #2126 among its holdings.

21 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

Mather Group held 34 shares of Xenon Pharmaceuticals worth $1.26K as of Q3 2026.
Xenon Pharmaceuticals was a new Mather Group position in Q3 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #2126 holding.
21 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.